Group 1: Market Performance - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index increased by 0.22% as of September 25, 2025, with notable gains from companies such as Jingwei Hengrun (up 6.46%) and Rongchang Bio (up 5.76%) [3] - The Sci-Tech 100 Index ETF (588030) also rose by 0.22%, with a latest price of 1.4 yuan, and has seen a cumulative increase of 2.73% over the past week [3] Group 2: AI Infrastructure Investment - Alibaba's CEO announced at the 2025 Alibaba Cloud Conference that the company is actively advancing a 380 billion yuan AI infrastructure project and plans to invest even more [4] - OpenAI, Oracle, and SoftBank revealed plans to build five new AI data centers in the U.S. under the "Gateway to the Stars" initiative, with total investments expected to exceed 400 billion dollars over the next three years [4] Group 3: Pharmaceutical Developments - Heng Rui Medicine announced a licensing agreement for its innovative drug SHR-A1811 with Glenmark Specialty S.A., receiving an upfront payment of 18 million dollars and potential milestone payments up to 1.093 billion dollars [4] Group 4: ETF Insights - The Sci-Tech 100 Index ETF has shown significant growth, with a recent increase of 385 million yuan in scale, ranking second among comparable funds [6] - The ETF's recent net inflow was 4.1263 million yuan, with a total of 183 million yuan net inflow over the last five trading days [6] Group 5: Sector Composition - The top three sectors in the Sci-Tech 100 Index are Electronics (37.51%), Pharmaceutical Biology (18.97%), and Power Equipment (12.8%), highlighting a strong focus on technology [6][7] - The top ten weighted stocks in the index account for 23.82% of the total index, indicating concentrated investment in key players [7]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for its drug SHR7280, marking a significant step towards market approval for this oral GnRH receptor antagonist [1] Company Summary - The drug SHR7280 is an oral small molecule GnRH receptor antagonist designed to block the binding of endogenous GnRH to its receptor, thereby inhibiting the synthesis and release of luteinizing hormone (LH) and other gonadotropins [1] - SHR7280 is intended for use in controlled ovarian hyperstimulation treatments within assisted reproductive technology [1] Industry Summary - There are currently no approved oral GnRH antagonists in the domestic and international assisted reproductive fields, indicating a potential market opportunity for SHR7280 [1]

（文章来源：每日经济新闻） 每经AI快讯，9月25日，港股恒瑞医药(01276.HK)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交 额4737.84万港元。 ...

公开资料显示，Glenmark Specialty隶属于Glenmark Pharmaceuticals公司，后者是一家以研究为主导的全 球制药公司，总部位于印度孟买，于印度国家证券交易所以及孟买证券交易所上市，业务涵盖创新药、 仿制药及OTC领域，重点关注呼吸、皮肤及肿瘤学治疗领域。在四大洲拥有11家世界级生产设施，业务 覆盖80多个国家，2023年制药销售额位列生物制药公司前100名。 消息面上，恒瑞医药发布公告称，将公司具有自主知识产权的1类创新药瑞康曲妥珠单抗(SHR-A1811) 项目有偿许可给Glenmark Specialty。Glenmark Specialty将向恒瑞支付1800万美元首付款。恒瑞有资格获 得与注册和销售相关的里程碑付款，最高可达10.93亿美元。根据瑞康曲妥珠单抗在授权范围内的销售 情况，Glenmark Specialty将向恒瑞支付相应的销售提成。 恒瑞医药（600276）(01276)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交额4737.84万港元。 ...

公开资料显示，Glenmark Specialty隶属于Glenmark Pharmaceuticals公司，后者是一家以研究为主导的全 球制药公司，总部位于印度孟买，于印度国家证券交易所以及孟买证券交易所上市，业务涵盖创新药、 仿制药及OTC领域，重点关注呼吸、皮肤及肿瘤学治疗领域。在四大洲拥有11家世界级生产设施，业务 覆盖80多个国家，2023年制药销售额位列生物制药公司前100名。 消息面上，恒瑞医药发布公告称，将公司具有自主知识产权的1类创新药瑞康曲妥珠单抗(SHR-A1811) 项目有偿许可给Glenmark Specialty。Glenmark Specialty将向恒瑞支付1800万美元首付款。恒瑞有资格获 得与注册和销售相关的里程碑付款，最高可达10.93亿美元。根据瑞康曲妥珠单抗在授权范围内的销售 情况，Glenmark Specialty将向恒瑞支付相应的销售提成。 智通财经APP获悉，恒瑞医药(01276)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交额4737.84万 港元。 ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]

Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]

Group 1 - Heng Rui Medicine signed a licensing agreement with Glenmark Specialty S.A. for the drug Rykon Trastuzumab, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion based on sales performance [1] - The drug Rykon Trastuzumab targets HER2 and is approved for treating HER2-mutated non-small cell lung cancer, enhancing Heng Rui's overseas market presence and innovative brand image [1] Group 2 - Tian Shi Li's subsidiary received approval for clinical trials of TSL2109 capsules, a novel dual-target small molecule inhibitor for advanced solid tumors, marking a first in the global market [2] - The company is actively transforming into innovative pharmaceuticals, with TSL2109 representing a significant step in its product development strategy [2] Group 3 - Kang Tai Bio's application for a trivalent influenza virus split vaccine has been accepted by the National Medical Products Administration, aimed at preventing influenza in individuals aged three and above [3] - The competitive vaccine market necessitates ongoing research and innovation for companies to maintain long-term core competitiveness, and successful approval of this vaccine would enhance Kang Tai's product portfolio [3]

Group 1 - President Xi Jinping announced China's new round of Nationally Determined Contributions at the UN Climate Change Summit, aiming for a 7%-10% reduction in greenhouse gas emissions by 2035, with non-fossil energy consumption exceeding 30% of total energy consumption [3] - The total installed capacity of wind and solar power is targeted to reach over 360 million kilowatts, six times that of 2020, and forest stock is expected to exceed 24 billion cubic meters [3] - The national carbon emissions trading market will cover major high-emission industries, and a climate-adaptive society is to be fundamentally established [3] Group 2 - Premier Li Qiang emphasized China's commitment to maintaining an open trade and investment market during a meeting with the President of the European Commission, urging fair competition and adherence to WTO rules [5] - The Chinese government will not seek new special and differential treatment in current and future WTO negotiations, reinforcing its role as a responsible developing country [5] - The People's Bank of China announced a 600 billion yuan MLF operation on September 25, marking a net injection of 300 billion yuan for the month, continuing a trend of high liquidity [5][6] Group 3 - Alibaba announced a collaboration with NVIDIA on Physical AI, with plans to invest 380 billion yuan in AI infrastructure and the launch of seven large model products, including Qwen3-Max, the largest and most capable model to date [4] - The Chinese Ministry of Commerce introduced 14 measures to promote digital consumption, including trials for smart connected vehicles and drone delivery services [6] Group 4 - The A-share market saw significant gains, with the Shanghai Composite Index rising 0.83% to 3853.64 points, and the ChiNext Index increasing by 2.28% [8] - The Hong Kong Hang Seng Index rose 1.37%, with notable gains in tech stocks like Alibaba and SMIC, while medical stocks faced declines [8] - Chery Automobile announced its H-share final offering price at 30.75 HKD per share, set to officially list on September 25 [8] Group 5 - The State Administration for Market Regulation is seeking public opinion on new standards for food delivery platforms, addressing issues like competition and delivery personnel rights [11] - The National Press and Publication Administration approved 145 domestic games and 11 imported games in September, indicating a positive trend in the gaming industry [12] Group 6 - The global crude steel production in August was 145.3 million tons, a year-on-year increase of 0.3%, while the cumulative production from January to August saw a decline of 1.7% [23] - The UK government faced challenges in issuing new bonds, with the latest five-year bond auction seeing the lowest oversubscription rate in nearly two years [20]

关于与Glenmark Specialty公司签署 瑞康曲妥珠单抗项目授权许可协议的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-153 江苏恒瑞医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"恒瑞"或"公司"）与Glenmark Specialty S.A.（以下简 称"Glenmark Specialty"）达成协议，将公司具有自主知识产权的1类创新药瑞康曲妥珠单抗（SHR- A1811）项目有偿许可给Glenmark Specialty。 一、许可产品基本信息 1、首付款 Glenmark Specialty 将向恒瑞支付1800万美元首付款。 瑞康曲妥珠单抗是恒瑞自主研发的以HER2为靶点的抗体偶联药物（ADC），可通过与HER2表达的肿 瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素，诱导细胞周期阻滞从而诱导肿瘤细 胞凋亡。其释放的毒素具有高透膜性，可发挥旁观者杀伤效应，进一步 ...